Recently, 10 hospitals in China have implanted Medtronic's new generation of cardiac resynchronization defibrillator Viva XT CRT-D and buried cardioverter defibrillator Evera S ICD. Both defibrillators are developed by Medtronic, with longer battery life, smarter and more physiologic functions, and a more conformable shape. These two new defibrillators have been marketed in the US and Europe and have been widely used clinically.

The application of Viva XT CRT-D improves the CRT response rate by 12% and is simpler and more effective than traditional cardiac ultrasound optimization. Compared with previous CRT-D clinical trials, Viva XT CRT-D was shown to reduce heart failure hospitalization and mortality by 21% in the first year of implantation. Economic analysis presented at the International Conference on Pharmaceutical Economics (ISPOR Europe) shows that Viva XT CRT-D will reduce the overall medical cost of both the payer and the hospital compared to traditional algorithmic CRT-D devices.

The increase in CRT response rate is due to the fact that AdaptivCRT can intelligently adjust adaptive left ventricular pacing and dual chamber pacing according to different patients' different states, and dynamically optimize the interventricular (AV) and interventricular (VV) intervals. Reducing unnecessary right ventricular pacing, for the first time in the industry to achieve personalized medical goals, to achieve "dynamic optimization, jump with your heart."

EVERA S ICD can be said to be "internal and external repair, excellence", its DF4 multi-pole integrated integrated standard interface, making implantation easier, postoperative comfort and infection risk is lower. SmartShock intelligent shock function to improve the quality of life of patients; new battery capacitance technology to provide patients with maximum security and economic value.

The new generation of Viva XT CRT-D and Evera S ICD's PhysioCurve streamlined case design is more in line with the human physiological engineering mechanics curve, which can reduce the pressure on the skin of the device by more than 30% compared with other devices. After implantation, it can better fit the skin of the chest, thereby reducing the risk of rupture and infection of the capsular bag, improving the postoperative aesthetics, and benefiting the slim Chinese patients.

Seven independent studies have shown that Medtronic is the industry leader in battery life. Using this as a platform, the innovative battery technology of Medtronic Viva and Evera systems extends the service life by 10-25% (up to 11 years).

The new generation of SmartShock2.0 smart shock algorithm with Viva and Evera products has stronger discriminating ability and greatly reduces the occurrence of misdischarge. Clinical studies found that 98.2% of patients had no inappropriate discharge 1 year after applying SmartShock.

“The new generation of defibrillators has obvious clinical advantages, which makes the operation easier, the surgical wounds are more beautiful, and the functional treatment is more physiological.” The implant doctor who participated in the operation last week said: “The new function has been greatly reduced. The phenomenon of accidental discharge and the risk of postoperative infection, the patient's program-controlled follow-up has become easier, hope to bring better clinical efficacy to patients, improve the quality of life of patients and their families."

“These products can reduce patient hospitalization and mortality, improve overall quality of life for patients, and provide new options for doctors and patients,” said Lin Song, director of cardiac rhythm disease management at Medtronic Greater China. “Essentially ergonomics Curves, longer lifespans, and more physiological CRT-D optimization algorithms are expected to provide patients with more effective treatment options."

Medtronic collaborates with clinical experts, researchers and scientists worldwide to provide the broadest range of innovative medical technologies for cardiovascular and cardiac rhythm interventions and surgical treatments. Medtronic is committed to providing healthcare consumers and healthcare providers around the world with products or services that create clinical and economic value.

Juice Drinks

Fruit juice drinks is a beverage made of fruit juice products obtained by physical methods such as pressing, centrifugation and extraction. Fruit juice retains most of the nutrients in the fruit, such as vitamins, minerals, sugar and pectin in dietary fiber. Often drinking fruit juice can help digestion, moisten the intestines and supplement the lack of nutrients in the diet.
There are two kinds of fruit juice: pure fruit juice and compound fruit juice. As far as pure fruit juice is concerned, it can be divided into two types: one is to directly use the original juice, and the other is to dehydrate the freshly squeezed fruit juice first, and then add water to reduce it into concentrated fruit juice. Most pure fruit juices are concentrated. AGOLYN offers various flavors of honey tea, such as honey Citron tea etc.

Juice Drinks,Honey Tea,Honey Citron Tea,Goji Berry Juice

Xi'an Gawen Biotechnology Co., Ltd , https://www.seoagolyn.com